CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine trains immune system to fight advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether a personalized vaccine made from each patient's unique tumor proteins can safely boost the immune system against advanced breast cancer, melanoma, and lung cancer. The vaccine is given along with an immune-boosting drug (nivolumab) and an…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 16:47 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if the combination is safe and helps the immune system fight cancer more effectively. Ab…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
Immune cell attack: new combo therapy targets brain tumors in advanced melanoma
Disease control Recruiting nowThis study tests a new treatment for people with stage IV melanoma that has spread to the brain. It combines a chemotherapy drug (temozolomide) with specially grown immune cells (NK cells) from a healthy donor. The goal is to see if this combination is safe and can shrink brain t…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Kari Kendra • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New hope for kidney transplant patients with advanced skin cancer
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
New drug combo trial hopes to tame tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like melanoma, ovarian, or head and neck cancers) that haven't responded to standard treatments. The main goal is to find the safest dose and under…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
Spinal immunotherapy injection shows promise for tough Brain-Lining cancers
Disease control Recruiting nowThis early-phase trial is testing whether the immunotherapy drug nivolumab can be safely given both into a vein and directly into the fluid around the spinal cord for people with melanoma or lung cancer that has spread to the lining of the brain. About 75 participants will receiv…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
New drug combo aims to shrink brain tumors in advanced melanoma
Disease control Recruiting nowThis phase II trial is testing two oral drugs, binimetinib and encorafenib, in 35 adults with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The study aims to see if this combination can control the disease and improve surviva…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Biomarker-Guided combo aims to outsmart resistant cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted drug) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head/neck cancers that have stopped responding to prior immunotherapy. Researchers will also see if two tumor bi…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Morning vs. evening: can timing boost melanoma treatment?
Disease control Recruiting nowThis study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly as…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
Flu vaccine injected into tumors shows promise against melanoma
Disease control Recruiting nowThis early-stage trial is testing whether injecting a flu vaccine directly into melanoma tumors can help shrink them. The study includes adults with stage I to IV melanoma who have at least one tumor that can be injected. The main goals are to find the safest dose and to see what…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Carlo Contreras • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New hope for melanoma brain metastases: which drug combo works best?
Disease control Recruiting nowThis study tests two different drug combinations in people with a specific type of melanoma (BRAF-V600 mutant) that has spread to the brain. One group gets a targeted therapy plus an immunotherapy, while the other gets two immunotherapies. The goal is to see which approach better…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Cancer care at home: a new study tests if shots are better than clinic visits
Symptom relief Recruiting nowThis study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it in a clinic. It aims to reduce the time, cost, and stress of traveling for treatment. About 50 adults with various advanced cancers will try both settings and report which they…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 17, 2026 12:04 UTC
-
Could a poop transplant fix cancer treatment side effects?
Knowledge-focused Recruiting nowThis study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC
-
Can t cell clues predict immunotherapy success?
Knowledge-focused Recruiting nowThis study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to understand why so…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:57 UTC